Symbyax - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:45Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Neuroleptics]]
			[[Category:Antidepressants]]
			[[Category:Mood stabilizers]]
			[[Category:Fixed-dose combinations]]

MDElliottMD: home-claude house-rule fix (terminology)

2026-05-23T04:50:58Z

home-claude house-rule fix (terminology)

← Older revision		Revision as of 04:50, 23 May 2026
Line 15:		Line 15:
	\| bioavailability = Olanzapine 60% (oral); fluoxetine high (oral)<ref name="symbyax-label" />		\| bioavailability = Olanzapine 60% (oral); fluoxetine high (oral)<ref name="symbyax-label" />
	\| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}		\| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-~~antipsychotic~~ '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />
	\| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.		\| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.
	}}		}}

MDElliottMD: parser-claude housekeeping, em-dash to comma per style rule

2026-05-23T04:45:11Z

parser-claude housekeeping, em-dash to comma per style rule

← Older revision		Revision as of 04:45, 23 May 2026
Line 16:		Line 16:
	\| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}		\| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-antipsychotic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-antipsychotic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />
	\| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression — risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy — by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.		\| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.
	}}		}}

	== References ==		== References ==
	<references />		<references />

MDElliottMD: parser-claude batch MedTemplate pre-fill, mind-medicine combination

2026-05-23T04:44:11Z

parser-claude batch MedTemplate pre-fill, mind-medicine combination

New page

{{MedTemplate
| generic = Olanzapine / Fluoxetine
| brand = Symbyax
| structure =
| classes = [[:Category:Neuroleptics|Atypical neuroleptic (olanzapine)]], [[:Category:Antidepressants|Antidepressant (fluoxetine, SSRI)]], [[:Category:Mood_stabilizers|Mood stabilizer]], [[:Category:Fixed-dose_combinations|Fixed-dose combination]]
| uses = <vote slug="bipolar-depression-use">Bipolar I depression (acute)</vote>, <vote slug="treatment-resistant-depression-use">Treatment-resistant major depression (after at least two SSRI failures)</vote>
| starting_dose = 6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability
| preparations = Capsules: 3/25, 6/25, 6/50, 12/25, 12/50 mg olanzapine/fluoxetine
| fda_max = 18 mg olanzapine / 75 mg fluoxetine per day
| pill_id =
| routes = Oral
| onset = Mood improvement at 1-3 weeks; full effect 4-6 weeks
| duration = 24 hours
| halflife = Olanzapine ~30 hours; fluoxetine 1-4 days (norfluoxetine 7-15 days)<ref name="symbyax-label">FDA Prescribing Information, Symbyax (olanzapine / fluoxetine HCl), Eli Lilly, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021520s041lbl.pdf</ref>
| bioavailability = Olanzapine 60% (oral); fluoxetine high (oral)<ref name="symbyax-label" />
| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-antipsychotic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />
| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression — risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy — by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.
}}

== References ==
<references />